Bolt Biotherapeutics, Inc. (BOLT) AI Stock Analysis

Headquartered in Redwood City, California, Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies that harness the immune system to eliminate tumor cells. The company's lead pipeline program is BDC-1001, a HER2-targeting agent in Phase I/II clinical trials for patients with HER2-expressing solid tumors, including those with HER2-low expression. Additional pipeline programs include BDC-2034, which targets carcinoembryonic antigen across colorectal, non-small cell lung, pancreatic, and breast cancers, and BDC-3042, an agonist antibody targeting Dectin-2 receptors on macrophages. Bolt Biotherapeutics is also exploring a PD-L1 program for tumors resistant to traditional checkpoint inhibitors.

Bolt Biotherapeutics generated $1.3M in revenue in FY2021, which expanded to $5.7M in FY2022 and $7.9M in FY2023 before reaching $7.7M in both FY2024 and FY2025. Between FY2020 and FY2025, revenue grew at a 5-year CAGR of 101.6%. Operating margin improved from -7364.1% in FY2021 to -450.1% in FY2025. Annual net losses narrowed from -$98.6M in FY2021 to -$33.4M in FY2025, while research and development expenses declined from $75.7M to $28.5M over the same timeframe. In the latest quarter ended June 30, 2026, quarterly revenue declined 99.7% year-over-year, and trailing twelve-month revenue totaled $4.7M with an EPS of -$16.51.

As of June 30, 2026, Bolt Biotherapeutics held $17.6M in cash and short-term investments and $21.6M in total debt, resulting in net debt of $4.0M. The company reported a current ratio of 2.61, total assets of $40.3M, and shareholders' equity of $12.6M, which equates to a debt-to-equity ratio of 1.71. Operating cash flow in FY2025 was -$39.9M, while free cash flow stood at -$39.9M after accounting for capital expenditures of $72,000.

Bolt Biotherapeutics has a market capitalization of $7.7M and an enterprise value of $11.0M. The stock trades at a price-to-sales multiple of 1.6x, compared to 4.1x for the median of its US-listed Healthcare peers. Its enterprise value-to-revenue multiple is 2.4x, while EV to EBITDA stands at 0.9x versus the peer median of 12.0x. The price-to-book ratio is 0.6x. Over the past year, BOLT shares returned -31.8%, compared to a 16.8% return for the S&P 500 (SPY), while its 5-year return is -98.5% versus 83.0% for the index.

Wall Street coverage on Bolt Biotherapeutics consists of 2 Strong Buy ratings and 2 Hold ratings. The mean price target is $29.00, representing 625.0% upside relative to the last closing price of $4.00. For the fiscal year ending December 31, 2026, analysts estimate revenue of $200,000 and EPS of -$26.29. For FY2027, 2 analysts project revenue of $3.5M and EPS of -$20.19. The company beat EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 11, 2026.

This page is an AI-written research summary of Bolt Biotherapeutics, Inc. (BOLT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BOLT income statement, BOLT balance sheet, BOLT key metrics, BOLT analyst forecast, BOLT chart. See the BOLT stock overview for the latest quote and news.